Abstract
Clinical diagnosis of mismatch repair defects has recently been complicated by the discovery of multiple gene alterations that lead to an expanded tumor spectrum. Studies of mismatch repair protein function will improve our understanding of this process and result in better prognostic indicators of mismatch repair-associated tumor development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bocker, T., Ruschoff, J. & Fishel, R. Molecular diagnostics of cancer predisposition: hereditary non-polyposis colorectal carcinoma and mismatch repair defects. Biochim. Biophys. Acta 31, 1–10 (1999).
Dietmaier, W. et al. Diagnostic microsatellite instability—definition and correlation with mismatch repair protein expression. Cancer Res. 57, 4749–4756 (1997).
de Wind, et al. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch repair protein functions. Nature Gen. 23, 359–362 (1999).
Wijnen, J., et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nature Gen. 23, 142–144.
Kolodner, et al. Germline MSH6 mutation in colorectal cancer families. Cancer Res. 59, 5068–5074 (1999).
Gradia, S., Acharya, S. & Fishel, R. The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. Cell. 91, 995–1005 (1997).
Fishel, R. Mismatch repair, molecular switches, and signal transduction. Genes and Dev. 12, 2096–2101 (1998).
Gradia, S. et al. hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA. Mol. Cell 3, 255–261 (1999).
Loeb, L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075–3079 (1991).
Aebi, S. et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56, 3087–3090 (1996).
Karran, P. & Bignami, M. Self-distruction and tolerance in resistance of mammalian cells to alkylation damage. Nucl. Acids Res. 20, 2933–2940 (1992).
Davis, T.W. et al. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res. 58, 767–778 (1998).
Edelmann, W. et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 91, 467–477 (1997).
Ruschoff, J. et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc. Natl. Acad. of Sci. USA 95, 11301–11306 (1998).
Zhang, H. et al. Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res. 59, 3021–3027 (1999).
Akiyama, Y. et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res. 57, 3920–3923 (1997).
Miyaki, M. et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nature Gen. 17, 271–272 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fishel, R. Signaling mismatch repair in cancer. Nat Med 5, 1239–1241 (1999). https://doi.org/10.1038/15191
Issue Date:
DOI: https://doi.org/10.1038/15191
This article is cited by
-
The mechanism of mismatch repair and the functional analysis of mismatch repair defects in Lynch syndrome
Familial Cancer (2013)
-
Large conformational changes in MutS during DNA scanning, mismatch recognition and repair signalling
The EMBO Journal (2012)
-
MutS switches between two fundamentally distinct clamps during mismatch repair
Nature Structural & Molecular Biology (2011)
